Cerebrospinal fluid proteomics in patients with Alzheimer's disease reveals five molecular subtypes with distinct genetic risk profiles
BM Tijms, EM Vromen, O Mjaavatten, H Holstege… - Nature aging, 2024 - nature.com
Alzheimer's disease (AD) is heterogenous at the molecular level. Understanding this
heterogeneity is critical for AD drug development. Here we define AD molecular subtypes …
heterogeneity is critical for AD drug development. Here we define AD molecular subtypes …
Exploring the interaction between T-cell antigen receptor-related genes and MAPT or ACHE using integrated bioinformatics analysis
W Guo, X Gou, L Yu, Q Zhang, P Yang, M Pang… - Frontiers in …, 2023 - frontiersin.org
Alzheimer's disease (AD) is a neurodegenerative disease that primarily occurs in elderly
individuals with cognitive impairment. Although extracellular β-amyloid (Aβ) accumulation …
individuals with cognitive impairment. Although extracellular β-amyloid (Aβ) accumulation …
Large-scale cerebrospinal fluid proteomic analysis in Alzheimer's disease patients reveals five molecular subtypes with distinct genetic risk profiles
BM Tijms, EM Vromen, O Mjaavatten, H Holstege… - medRxiv, 2023 - medrxiv.org
Alzheimer's disease (AD) is heterogenous on the molecular level. Understanding this
heterogeneity is critical for AD drug development. We aimed to define AD molecular …
heterogeneity is critical for AD drug development. We aimed to define AD molecular …
Detection of APP gene recombinant in human blood plasma
S Mitsunaga, N Fujito, H Nakaoka, R Imazeki… - Scientific Reports, 2023 - nature.com
The pathogenesis of Alzheimer's disease (AD) is believed to involve the accumulation of
amyloid-β in the brain, which is produced by the sequential cleavage of amyloid precursor …
amyloid-β in the brain, which is produced by the sequential cleavage of amyloid precursor …
Limitations of the human iPSC-derived neuron model for early-onset Alzheimer's disease
P Valdes, KW Henry, MQ Fitzgerald, K Muralidharan… - Molecular Brain, 2023 - Springer
Non-familial Alzheimer's disease (AD) occurring before 65 years of age is commonly
referred to as early-onset Alzheimer's disease (EOAD) and constitutes~ 5–6% of all AD …
referred to as early-onset Alzheimer's disease (EOAD) and constitutes~ 5–6% of all AD …
Multi‐omics analyses highlight molecular differences between clinical and neuropathological diagnoses in Alzheimer's disease
Both clinical diagnosis and neuropathological diagnosis are commonly used in literature to
categorize individuals as Alzheimer's disease (AD) or non‐AD in omics analyses. Whether …
categorize individuals as Alzheimer's disease (AD) or non‐AD in omics analyses. Whether …
Impaired Mitochondrial Energy Metabolism Regulated by p70S6K: A Putative Pathological Feature in Alzheimer's Disease
W Gu, X Cong, Y Pei, NM Che Ajuyo, Y Min, D Wang - Metabolites, 2024 - mdpi.com
Alzheimer's disease (AD) is a neurodegenerative disease. Mitochondrial energy metabolism
and p70 ribosomal protein S6 kinase (p70S6K) play significant roles in AD pathology …
and p70 ribosomal protein S6 kinase (p70S6K) play significant roles in AD pathology …
TREM2 在阿尔茨海默病中的研究进展.
王诗铫, 黄志航, 蒋腾 - Journal of Nanjing Medical …, 2024 - search.ebscohost.com
阿尔茨海默病(Alzheimer'sdisease, AD) 是最常见的神经退行性疾病. 大量证据表明,
遗传因素在AD 的发病机制中起重要作用. 2 型髓系细胞触发受体(triggering receptor expressed …
遗传因素在AD 的发病机制中起重要作用. 2 型髓系细胞触发受体(triggering receptor expressed …
[HTML][HTML] Identification and Correlation of Novel Genes Associated with Progression of Alzheimer's Disease
T Arora, P Jain, H Sharma, V Prashar… - Gene …, 2024 - xiahepublishing.com
Methods Employing the robust tools of R-language, we dissected vast RNA sequence
datasets comprising numerous samples and thousands of genes, pinpointing potential …
datasets comprising numerous samples and thousands of genes, pinpointing potential …
Integrative multiomics reveals common endotypes across PSEN1, PSEN2, and APP mutations in familial Alzheimer's disease
P Valdes, AB Caldwell, Q Liu, MQ Fitzgerald… - 2022 - researchsquare.com
Background Mutations in PSEN1, PSEN2, and APP can lead to Alzheimer's disease (AD)
with an early age at onset (AAO) and hallmark progressive cognitive decline. These …
with an early age at onset (AAO) and hallmark progressive cognitive decline. These …